FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/New Phase 3 Study Investigates EloraTZP for Weight Loss in Diabetes and Obesity Patients
返回研究图书馆

New Phase 3 Study Investigates EloraTZP for Weight Loss in Diabetes and Obesity Patients

November 20, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

New Phase 3 Study Investigates EloraTZP for Weight Loss in Diabetes and Obesity Patients

Eli Lilly and Company has launched a new Phase 3 clinical trial to explore the effectiveness of EloraTZP, a coformulation of eloralintide and tirzepatide, compared to tirzepatide alone. This study aims to provide valuable insights into how this innovative peptide therapy can help individuals with obesity or overweight conditions who also have type 2 diabetes manage their weight more effectively.

Background

The prevalence of obesity and type 2 diabetes continues to rise globally, posing significant challenges for healthcare providers and researchers alike. Current treatment options often fall short in addressing the complex interplay between these conditions. EloraTZP combines two peptides: eloralintide, which targets appetite regulation, and tirzepatide, a glucagon-like peptide-1 (GLP-1) receptor agonist that also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. This combination therapy is designed to enhance weight loss outcomes while maintaining blood sugar control.

The Phase 3 trial, registered on ClinicalTrials.gov under identifier NCT07881458, seeks to evaluate whether EloraTZP offers superior benefits over tirzepatide alone in reducing body weight and improving glycemic control. With participation spanning approximately two years, the study will provide a comprehensive assessment of long-term efficacy and safety.

Key Details

The study is recruiting adult participants diagnosed with obesity or overweight conditions along with type 2 diabetes. Researchers aim to determine if EloraTZP can deliver better results than tirzepatide in terms of weight reduction and metabolic health improvements. Participants will undergo rigorous monitoring throughout the trial period, allowing researchers to gather detailed data on both short-term outcomes and long-term effects.

Eli Lilly's commitment to advancing peptide therapy underscores the growing importance of innovative treatments for chronic conditions like obesity and diabetes. By investigating EloraTZP’s potential benefits, this study could pave the way for more effective management strategies that address multiple health concerns simultaneously.

Key Takeaways

  • Innovative Combination Therapy: The trial explores a new coformulation of eloralintide and tirzepatide to enhance weight loss efficacy.
  • Long-term Evaluation: Participants will be monitored over two years, providing comprehensive data on sustained benefits and safety profiles.
  • Targeted Patient Population: The study focuses on individuals with obesity or overweight conditions alongside type 2 diabetes, addressing a critical health need.
  • Potential for Improved Outcomes: Results could lead to more effective treatment options for managing both weight and blood sugar levels.

What This Means

For the peptide research community, this trial represents an important step forward in understanding how combined therapies can address complex medical conditions. As obesity and diabetes continue to impact millions of lives worldwide, findings from this study may offer new hope for patients seeking more effective management options. Additionally, successful outcomes could influence future regulatory decisions and clinical guidelines, further solidifying the role of peptide therapy in modern healthcare.

---

Source: ClinicalTrials.gov — Published 7 November 2026

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。